Expert Interviews

Laynie Dratch, ScM, CGC, discusses the prognosis associated ALS.

Treatment barriers inhibit optimal care for many patients diagnosed with HIV.

Dr. Peskin identifies the significance of payer support in the treatment landscape of MDR HIV.

Jennifer Roggenbuck, MS, LGC, opens a discussion on patient journeys with ALS.

Non–treatment-naïve patient considerations are explored by key opinion leaders.

Medical experts provide an overview of testing considerations for MDR HIV.

In this second part of a two-part video series, Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care.

Bronwyn Spira of Force Therapeutics talked to Managed Healthcare Executive about CMS' new CPT codes that were introduced in 2022. These codes focus on musculoskeletal and respiratory conditions and the data collected from patients affected. According to Spira, these codes help more patients in underserved populations receive better access to care as barriers like cost and transportation are removed through remote care.

Steven Peskin, M.D., MBA, FACP, discusses considerations for payers when identifying patients at risk for drug-resistant HIV.

Health disparities in HIV treatment management are discussed by Drs Peskin and McCray.

Rich Priore, Sc.D., M.H.A., a clinical associate professor in the Department of Health Policy and Management at Tulane University addresses how hospitals will be affected on the cost and revenue side after the COVID-19 Public Health Emergency expires May 11.

The trade association began lobbying in 2019.

Chris Blackley, co-founder and chief executive officer of Prescryptive Health, discusses the laws that states that are implementing to restrict PBM practices and the impact on patients and employers.

Under the Consolidated Appropriations Act of 2023, some Medicare telehealth flexibilities will extend until December 31, 2024, though significant questions remain for the future of telehealth, especially in the Medicare program.

Rich Priore, Sc.D., M.H.A., a clinical associate professor in the Department of Health Policy and Management at Tulane University, said if Americans invested in health prevention and wellness, fewer would be in hospitals and the cost of care would lower.

Founder and managing partner of Third Culture Capital (3CC), Julien Pham, expressed that funding for telehealth is on the decline and will only continue on this path. Pham explained why this is happening and shared alternative routes of care organizations can take to address disparities and improve access to care.

In this video, Dea Belazi, president and chief executive officer of AscellaHealth, discusses how payers will approach specialty drugs.

Dr McCray shares an encounter with “Patient X”, highlighting the barriers and challenges associated with MDR therapies in HIV treatment.

Dr McCray shares an encounter with “Patient X”, highlighting the barriers and challenges associated with MDR therapies in HIV treatment.

In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.

Douglas K. Devries, OD, shares his final insights, highlighting prospective emerging treatments for Demodex blepharitis.

John Brandsema, MD, and Julie Parsons, MD, discuss considerations for combination SMA treatment and factors impacting SMA care pathways, such as prior authorization and multistep therapies.

In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.

Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.

Medical experts provide insights on factors impacting SMA treatment strategies.

Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, talks about why shortening this gap is critical to ensuring better patient outcomes and shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. This is the first part of a three-part video series.

A lack of guidelines impair the management of Demodex blepharitis.

Disease-modifying treatments are highlighted as key contributors to the optimization of SMA management.

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Douglas K. Devries, OD, discusses how Demodex blepharitis affects patients’ quality of life and associated financial burden.